-
Korro Announces Selection of its First Development Candidate for the Potential Treatment of Alpha-1 Antitrypsin Deficiency (AATD)
-
Korro Bio Appoints Dr. Rachel Meyers to Board of Directors
-
Korro Bio and Frequency Therapeutics Announce Closing of Merger and Private Placement of $117 Million
-
Korro Bio Announces Appointment of Tim Pearson to Board of Directors Upon Closing of the Proposed Merger and Promotion of Todd Chappell to Chief Operating Officer
-
Korro Bio and Frequency Therapeutics Announce Merger Agreement
-
Korro Strengthens Leadership Team with Appointment of Shelby Walker as General Counsel
-
Korro Bio and Genevant Sciences Enter into Collaboration Agreement to Develop RNA Editing Therapeutic for Alpha-1 Antitrypsin Deficiency
-
Korro Bio Appoints Dr. Steve Colletti as Chief Scientific Officer
-
Korro Bio to Present at the 41st Annual J.P. Morgan Healthcare Conference
-
Korro Bio Expands Leadership Team with Key Appointments
-
Korro Bio to Participate in 2022 Jefferies Healthcare Conference
-
Korro Bio Completes $116M Series B Financing to Expand the Frontier of Genetic Medicine through its Pipeline of RNA Editing Programs
-
Korro Bio to Present at the 40th Annual J.P. Morgan Healthcare Conference
-
Korro Bio to Present at the Evercore ISI 4th Annual HealthCONx Conference and the Piper Sandler 33rd Annual Virtual Healthcare Conference
-
Korro Bio Chief Executive Officer Ram Aiyar, Ph.D., MBA, to Participate in September Investor Conferences
-
Korro Bio Chief Executive Officer Ram Aiyar, Ph.D., MBA, to Present at 2021 Jefferies Virtual Healthcare Conference
-
Korro Bio Appoints Vineet Agarwal as Chief Financial Officer
-
Korro Bio Strengthens Leadership Team with Appointment of Howard Stern M.D., Ph.D. as Chief Scientific Officer
-
Korro Bio Chief Executive Officer Ram Aiyar, Ph.D., MBA, to Present at Upcoming Conferences
-
Korro Bio to Present at J.P. Morgan Healthcare Conference
-
Korro Bio Appoints Ram Aiyar, Ph.D., MBA, as Chief Executive Officer
-
Korro Bio Appoints Omar Khwaja, M.D., Ph.D. to its Board of Directors
-
Korro Bio Closes $91.5 Million Series A Financing to Advance the Next Frontier in RNA Therapeutics
-
Korro Bio Launched to Advance Groundbreaking New Approach to Nucleic Acid Editing